, Jan. 4, 2012 /PRNewswire/ --
Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received warrant exercises generating a total of approximately
in cash proceeds. These warrant exercises bring the company's year-end cash balance to approximately
"This cash infusion, following the recent positive clinical results for use of our Symphony System, represents important achievements for Echo as we progress toward regulatory clearance and commercialization," said
Patrick T. Mooney
, M.D., Chairman and CEO of Echo Therapeutics. "We believe this additional capital strengthens the balance sheet and will provide greater flexibility in the accelerated product development and clinical validation of our products."
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude® SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended
December 31, 2010
, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio Director, Investor Relations and Corporate Communications (215)717-4104
Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at